291 related articles for article (PubMed ID: 28974538)
1. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
[TBL] [Abstract][Full Text] [Related]
2. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Modulation of BET Family in Sepsis.
Wang N; Wu R; Comish PB; Kang R; Tang D
Front Pharmacol; 2021; 12():642294. PubMed ID: 33776776
[TBL] [Abstract][Full Text] [Related]
7. Selective BET inhibitor RVX-208 ameliorates periodontal inflammation and bone loss.
Sun M; Clayton N; Alam S; Asmussen N; Wong A; Kim JH; Luong G; Mokhtari S; Pellei D; Carrico CK; Schwartz Z; Boyan BD; Giannobile WV; Sahingur SE; Lin Z
J Clin Periodontol; 2023 Dec; 50(12):1658-1669. PubMed ID: 37855275
[TBL] [Abstract][Full Text] [Related]
8. RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
Ghosh GC; Bhadra R; Ghosh RK; Banerjee K; Gupta A
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423226
[TBL] [Abstract][Full Text] [Related]
9. How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
Schooling CM; Zhao JV
Am J Cardiovasc Drugs; 2019 Apr; 19(2):107-111. PubMed ID: 30693439
[TBL] [Abstract][Full Text] [Related]
10. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
[TBL] [Abstract][Full Text] [Related]
11. An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis.
Offner H; Firestein GS; Boyle DL; Pieters R; Frincke JM; Garsd A; White SK; Reading CL; Auci DL
J Pharmacol Exp Ther; 2009 Jun; 329(3):1100-9. PubMed ID: 19297421
[TBL] [Abstract][Full Text] [Related]
12. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Picaud S; Wells C; Felletar I; Brotherton D; Martin S; Savitsky P; Diez-Dacal B; Philpott M; Bountra C; Lingard H; Fedorov O; Müller S; Brennan PE; Knapp S; Filippakopoulos P
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19754-9. PubMed ID: 24248379
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Gilan O; Rioja I; Knezevic K; Bell MJ; Yeung MM; Harker NR; Lam EYN; Chung CW; Bamborough P; Petretich M; Urh M; Atkinson SJ; Bassil AK; Roberts EJ; Vassiliadis D; Burr ML; Preston AGS; Wellaway C; Werner T; Gray JR; Michon AM; Gobbetti T; Kumar V; Soden PE; Haynes A; Vappiani J; Tough DF; Taylor S; Dawson SJ; Bantscheff M; Lindon M; Drewes G; Demont EH; Daniels DL; Grandi P; Prinjha RK; Dawson MA
Science; 2020 Apr; 368(6489):387-394. PubMed ID: 32193360
[TBL] [Abstract][Full Text] [Related]
14. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.
Bandukwala HS; Gagnon J; Togher S; Greenbaum JA; Lamperti ED; Parr NJ; Molesworth AM; Smithers N; Lee K; Witherington J; Tough DF; Prinjha RK; Peters B; Rao A
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14532-7. PubMed ID: 22912406
[TBL] [Abstract][Full Text] [Related]
16. Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine.
Singh MB; Babigian CJ; Sartor GC
Neuropharmacology; 2022 Jun; 210():109040. PubMed ID: 35314160
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
19. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S; Dzobo KE; Rakai BD; Kaiser Y; Versloot M; Bahjat M; Stotz SC; Fu L; Sweeney M; Johansson JO; Wong NCW; Stroes ESG; Kroon J; Kulikowski E
Clin Epigenetics; 2020 Nov; 12(1):166. PubMed ID: 33172487
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
